Keywords: roche, extends, hiv, portfolio, nnrti, in-licensed, mv026048

Roche extends HIV portfolio with NNRTI

Article | 29 April 2002

Print This

Roche has in-licensed MV026048, an HIV drug candidate that is expectedto enter Phase I clinical testing in 2003, from Swedish biotechnology ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in